Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immutep Limited - American Depositary Shares (NQ:IMMP)

2.700 -0.040 (-1.46%)
Streaming Delayed Price Updated: 1:27 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immutep Limited - American Depositary Shares

< Previous 1 2 3 Next >
News headline image
SurgePays (NASDAQ: SURG) Expands Growth Strategy – New Lead-Driver to Boost Fintech Revenue – More Stocks Inside
Via AB Newswire
Topics Artificial Intelligence
News headline image
What's going on in today's session ↗
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday. 
Via Chartmill
News headline image
Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa
From Immutep Limited
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer
From Immutep Limited
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo ↗
Immutep's efti combo with Keytruda and chemo shows a 60.8% response rate in lung cancer trial, with strong efficacy across PD-L1 expression levels. 
Via Benzinga
News headline image
Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer
From Immutep Limited
Via GlobeNewswire
News headline image
Unusual volume stocks in Wednesday's session ↗
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the stocks with an unusual volume in today's session. 
Via Chartmill
News headline image
In today's session, these stocks are experiencing unusual volume. ↗
In today's session, these stocks are experiencing unusual volume. 
Via Chartmill
News headline image
Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial ↗
Immutep's INSIGHT-003 Phase 1 trial reports promising survival data for 1L NSCLC treatment using eftilagimod alpha, Keytruda, and chemotherapy. 
Via Benzinga
News headline image
Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer
From Immutep Limited
Via GlobeNewswire
News headline image
Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Increases In September ↗
 
Via Benzinga
Topics Stocks
News headline image
Abbott, Integra LifeSciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday 
Via InvestorPlace
News headline image
Australia Based Cancer Focused Immutep's Lead Cancer Drug Shows 'Meaningful Response' In Untreated Head & Neck Cancer, Stock Soars ↗
Immutep announces results from Cohort B of the TACTI-003 Phase 2b trial. The combination of eftilagimod alfa and Merck's Keytruda shows a 35.5% ORR and 58.1% DCR in PD-L1 negative head and neck cancer... 
Via Benzinga
News headline image
Why Ericsson Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Levi Strauss Posts Mixed Results, Joins Walgreens, AeroVironment And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
Pre-market stock movers are worth checking out on Thursday as we dig into all of the biggest news moving shares this morning! 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday? ↗
Immutep releases preliminary results from TACTI-003 trial showing promising outcomes for first-line treatment of HNSCC patients without PD-L1 expression. Final data expected in H1 CY2024. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
From Immutep Limited
Via GlobeNewswire
News headline image
Cancer Focused Immutep's Stock Soars On Tuesday - Here's Why ↗
Immutep releases promising safety and efficacy data for 90mg eftilagimod alpha combined with paclitaxel in HR+/HER2- metastatic breast cancer. No serious adverse events were reported, and a 50% overall... 
Via Benzinga
News headline image
Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023
From Immutep Limited
Via GlobeNewswire
News headline image
Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer
From Immutep Limited
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.